Karuna Upbeat On New Antipsychotic Mechanism Data
Phase III Studies Could Begin For The Combination Therapy Next Year
Karuna Therapeutics’ top-line Phase II data for a combination of a centrally acting muscarinic agonist, xanomeline, and a peripherally acting muscarinic antagonist, trospium, were greeted with enthusiasm by investors and the Boston, MA-based biotech.
